AMG20210081 Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Gastrointestinal tumors
Colorectal cancer
First-Line-Therapy (Metastatic Disease/Hematology)
The aim of this study is to compare progression free survival (PFS) in treatment-naïveParticipants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receivingsotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
The above-mentioned sponsor of the clinical trial is developing a new therapy for patients with a colorectal carcinoma that has the KRAS p.G12C mutation. Therefore, the study drug called Sotorasib will be tested in the trial. The sponsor would like to assess the safety and tolerability of sotorasib in combination with panitumumab and FOLFIRI in comparison to FOLFIRI with or without bevacizumab-awwb and to find out whether side effects are caused.